Skip to content

Clinical trials

Phase 3 Waldenstrom Macroglobulinemia trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Waldenstrom Macroglobulinemia Phase: Phase 3 Clear all

29 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20011
20032
20051
20062
20073
20082
20091
20101
20134
20141
20161
20171
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed21
Unknown status4
Terminated2
Active, not recruiting1
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Memorial Sloan Kettering Cancer Center3
Alliance for Clinical Trials in Oncology2
European Organisation for Research and Treatment of Cancer - EORTC2
Fred Hutchinson Cancer Center2
Gilead Sciences2
BeiGene1
Case Comprehensive Cancer Center1
Cellectar Biosciences, Inc.1
Clatterbridge Centre for Oncology1
French Study Group on Chronic Lymphoid Leukemia1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Waldenstrom Macroglobulinemia29
Leukemia, Lymphocytic, Chronic, B-Cell23
Lymphoma, Follicular21
Lymphoma, Mantle-Cell21
Lymphoma, B-Cell, Marginal Zone20
Lymphoma, Large B-Cell, Diffuse20
Hodgkin Disease19
Lymphoma, Non-Hodgkin18
Lymphoma, Large-Cell, Immunoblastic17
Multiple Myeloma16

Trials

Showing 51 to 29 of 29. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.